Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2016
EMA publishes EPAR for Aerivio Spiromax
5 September 2016 - The EMA has published an EPAR for Teva Pharmaceuticals' version of GSK's Seretide/Advair. ...
Posted by Michael Wonder on 19 Aug 2016
European Commission grants marketing authorisation for Teva’s Cinqaero (reslizumab)
18 August 2016 - First intravenous anti-IL-5 biologic therapy for severe eosinophilic asthma now approved in Europe. ...
Posted by Michael Wonder on 08 Jul 2016
Novartis announces FDA approval of Xolair (omalizumab) for paediatric allergic asthma
7 July 2016 - Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and ...
Posted by Michael Wonder on 26 Jun 2016
Teva receives CHMP positive opinion for Cinqaero (reslizumab)
24 June 2016 - Add-on therapy targeting IL-5 in adults with severe eosinophilic asthma pending marketing authorization in Europe. ...
Posted by Michael Wonder on 17 May 2016
Prescription medicines: new or extended uses approved by the TGA
17 May 2016 - The TGA has published a list of the medicines it approved for new uses (new indications) ...
Posted by Michael Wonder on 01 May 2016
Teva announces FDA approval of ProAir RespiClick (salbutamol sulphate) inhalation powder for paediatric asthma patients ages 4 to 11
29 April 2016 - Teva Pharmaceuticals announced today that the U.S. FDA has approved ProAir RespiClick (salbutamol sulphate) inhalation powder for ...
Posted by Michael Wonder on 23 Mar 2016
FDA approves Cinqair to treat severe asthma
23 March 2016 - The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for ...
Posted by Michael Wonder on 05 Nov 2015
FDA approves Nucala to treat severe asthma
4 November 2015 - The U.S. FDA has approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment ...